GleamWall
中文EN

BTMD biote Corp.

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1819253 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.6%
TTM net income YoY-106.7%
TTM EPS YoY-108.9%
Revenue 3-yr CAGR-1.0%
Net income 3-yr CAGR—

Margins

Gross margin67.5%
Operating margin5.0%
Net margin-1.1%
FCF margin4.1%
EBITDA margin6.6%

Returns

ROE—
ROA-1.8%
ROIC (approx.)18.5%
Asset turnover1.68x

Leverage & solvency

Liabilities / assets156.6%
Debt / equity—
Current ratio1.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-7.26x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue3.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$43.33M$44.23M$44.94M$46.41M$47.96M$48.86M$48.99M$49.83M
Cost of revenue$14.00M$15.31M$13.98M$14.84M$13.54M$13.88M$12.61M$14.30M
Gross profit$29.33M$28.92M$30.95M$31.57M$34.42M$34.99M$36.38M$35.53M
SG&A expense$26.84M$32.43M$27.79M$24.74M$26.15M$24.22M$26.69M$32.76M
Operating income$2.49M-$3.51M$3.17M$6.83M$8.27M$10.77M$9.69M$2.77M
Pretax income$1.36M-$7.13M$3.34M$5.60M$8.45M$6.08M$17.45M-$1.22M
Income tax$796,000$296,000$662,000$2.99M-$765,000$2.15M$1.62M-$4.70M
Net income$407,000-$6.56M$2.28M$1.95M$8.19M$3.19M$13.72M$3.70M
EBITDA$2.96M-$3.10M$4.15M$7.78M$8.63M$11.04M$10.55M$3.90M
EPS (basic)0.01-0.230.07—0.260.100.44—
EPS (diluted)0.01-0.230.06—0.220.100.37—
Weighted avg. shares (diluted)27.42M28.63M36.00M—36.71M31.74M36.95M—
Balance sheet
Cash & equivalents$8.85M$11.17M$5.32M$24.12M$28.05M$19.60M$41.70M$39.34M
Receivables$7.29M$7.81M$7.40M$6.87M$7.97M$9.07M$7.76M$7.63M
Inventory$17.77M$18.33M$19.88M$19.06M$16.45M$12.13M$13.45M$14.85M
Current assets$41.76M$43.04M$36.36M$54.67M$57.12M$49.50M$68.68M$68.13M
PP&E, net$14.96M$12.85M$10.70M$10.75M$10.06M$9.93M$8.39M$6.97M
Goodwill$5.83M$5.83M$5.83M$5.83M$5.83M$5.83M$5.83M$5.83M
Intangibles$3.34M$3.65M$3.96M$4.27M$4.57M$4.88M$5.19M$5.50M
Total assets$101.70M$101.70M$89.03M$107.61M$111.32M$104.80M$123.38M$122.37M
Current liabilities$30.50M$30.10M$28.23M$44.99M$56.31M$50.54M$48.47M$51.51M
Short-term debt$3.12M$3.12M$6.25M$6.25M$6.25M$6.25M$6.25M$6.25M
Long-term debt$116.95M$118.38M$94.42M$95.78M$97.13M$98.49M$99.85M$101.20M
Total debt$120.07M$121.50M$100.67M$102.03M$103.38M$104.74M$106.10M$107.45M
Total liabilities$159.29M$159.89M$136.99M$158.01M$176.79M$183.64M$208.21M$224.57M
Shareholders' equity-$65.35M-$65.79M-$56.09M-$58.54M-$72.75M-$85.10M-$89.98M-$105.93M
Net debt$111.22M$110.33M$95.36M$77.91M$75.33M$85.14M$64.40M$68.11M
Cash flow statement
Operating cash flow$3.69M-$1.18M$3.90M$7.57M$14.07M$7.09M$6.47M$12.37M
Capital expenditure$2.58M$2.56M$362,000$1.08M$499,000$1.81M$1.63M$1.67M
Free cash flow$1.11M-$3.73M$3.54M$6.49M$13.57M$5.28M$4.84M$10.70M
Investing cash flow-$3.03M-$2.62M-$1.17M-$2.36M-$690,000-$1.96M-$1.85M-$1.31M
Financing cash flow-$2.97M$9.65M-$21.54M-$9.13M-$4.93M-$27.23M-$2.26M-$9.93M
Depreciation & amortization$468,000$411,000$980,000$951,000$364,000$270,000$857,000$1.14M
Stock-based compensation$1.34M$1.97M$1.76M$2.20M$2.41M$2.19M$2.13M$1.89M
Dividends paid$8,000$616,000$405,000$138,000$8,000$887,000$694,000$88,000
Share buybacks$1.36M$4.79M$1.07M$0———$0

Free plan shows the latest 8 periods; Pro shows all 25 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.